Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Chemo and Short Course RT for Rectal Cancer with Liver Metastasis
NCT03022734Phase 2Unknown
- Sponsor
- Yonsei University
- Start
- Sep 2016
- Primary completion
- Jan 2021
- Modality
- Antibody Conjugates, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab, bevacizumab, oxaliplatin, irinotecan, fluorouracil in rectal cancer, liver metastases, sponsored by Yonsei University. Status: unknown.
02
Drugs
cetuximabbevacizumaboxaliplatinirinotecanfluorouracil
03
Conditions
rectal cancerliver metastases
Beyond the preview
Go deeper on NCT03022734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03022734.